marcus evans north america conferences

9th Pharmacovigilance, Drug Safety & Risk Management

Pioneering Successful Prediction, Automation, Real World Data, and Sustained Regulatory Compliance

23-24 Oct 2019
Philadelphia, PA, United States of America

Conference Workshop

Maintaining Market Advantage in the Transition to Increased Use of Automation

This interactive workshop will provide attendees an inside look on best practices, lessons learned and optimal use of automation within drug safety and risk management.

Workshop Moderator:


Conference Workshop

Ensuring Regulatory Compliance through Enhanced Global Regulatory Intelligence with Sorrento Therapeutic

While drug manufacturers attempt to create a hold on innovative solutions for drug safety, maintaining compliance is essential for all PV departments at their core. Despite the constant changes in regulatory systems and requirements, companies must ensure their complete and total understanding of regulatory expectations. In order to do so, companies must create solutions for regulatory intelligence.

Workshop Moderator: Stephen Klincewicz

Company:VP Pharmacovigilance, Sorrento Therapeutic

Why You Should Attend

9th Pharmacovigilance, Drug Safety & Risk Management

With the constantly changing Pharmaceutical industry, ensuring companies have strong Pharmacovigilance procedures and processes are important to company and product success. The Biopharmaceutical industry has consistent pressure to ensure drug safety through the updates in the PV arena. Companies are looking to enhance their practices for proactive drug safety, leveraging artificial intelligence, and capitalizing on other Pharmacovigilance trends.

This 9th instalment of the Pharmacovigilance, Drug Safety & Risk Management conference will allow attendees to engage in discussions and experience lessons learned on the most effective solutions for conducting and improving drug safety.

Key Topics

  • Address signal detection through Risk-Based methodologies by incorporating data and software
  • Optimize Pharmacovigilance (PV) practices by identifying effective use of automation throughout the product lifecycle
  • Enhance proactive and predictive drug safety throughout clinical research to mitigate risks early on
  • Leverage Artificial Intelligence (AI) and Machine Learning (ML) to support overall drug safety and risk management
  • Create Innovative Procedures for Collecting Patient Data from Real-World Channels
  • Previous Attendees Include

    Bristol-Myers Squibb
    CSL Behring
    Eli Lilly and Company
    Frontier BPM
    Glaukos Corporation
    ICON Clinical Research Inc
    Jazz Pharmaceuticals
    Johnson & Johnson
    Kyowa Kirin
    Novartis Corporation
    Otsuka Pharmaceuticals
    Pharmacyclics LLC an Abbvie Company
    Sanofi Pasteur
    Takeda Pharmaceuticals

    Why Choose marcus evans?

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.

    Event Partners

    Practical Insights From

    Stephen Klincewicz
    Vice President Pharmacovigilance
    Sorrento Therapeutic

    Curtis Chang
    Senior Medical Director Pharmacovigilance
    Takeda Pharmaceutical

    William O'Brien
    Director, Medical Safety Assessment, Cardiovascular, Fibrosis and Severe Sepsis
    Bristol-Myers Squibb

    Lillian Kirk
    Director, Global Pharmacovigilance Case Management
    Alexion Pharmaceuticals

    Linda Lum
    Director, Global Pharmacovigilance and Epidemiology
    Bristol-Myers Squibb

    Meenal Patwardhan
    TA Head for Safety

    Rosalina Domin
    QA and Deviation Management Head, Senior Director, Global Pharmacovigilance Quality-MCCQ

    Kenneth Lipetz
    Global Patient Safety Medical Business Advisor/GPS Medical Process Owner
    Eli Lilly and Company

    Click Here For Full Agenda

    Voice of Our Customers
    • “I find the 2 day event to be packed full of information to proactively assist current regulatory & strategic challenges in Pharmacovigilance.” –Sanofi
    • “Very informative & interesting while stayed focused in PV/Risk Management. I’m very impressed with the knowledge of the speakers”. – Allergan
    • “I really enjoyed and took lots of information back with me. Had ongoing changes discussed and future topics which made two days very interesting.” – EMD Serono
    • “Great forum for drug safety/PV, epidemiology and regulatory colleagues to collaborate and learn in a very focused forum.” - Gilead Sciences
    Join the Discussion

    Follow on LinkedIn

    Event Contact

    For all enquiries regarding speaking, sponsoring and attending this conference contact:

    Melini Hadjitheori

    PO Box 24797
    CY-1304 Nicosia

    +357 22 849 308
    Fax: +357 22 849 394